Sterling Financial Planning Inc. trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 600 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Sterling Financial Planning Inc.’s holdings in Gilead Sciences were worth $39,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in GILD. Barrett Asset Management LLC increased its holdings in Gilead Sciences by 333.0% during the fourth quarter. Barrett Asset Management LLC now owns 433 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 333 shares during the last quarter. TFO TDC LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth $26,000. Tortoise Investment Management LLC boosted its stake in shares of Gilead Sciences by 81.6% in the 4th quarter. Tortoise Investment Management LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 200 shares in the last quarter. Graves Light Private Wealth Management Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $27,000. Finally, Joseph P. Lucia & Associates LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $29,000. 76.36% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP Brett A. Pletcher sold 1,975 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 10th. The shares were sold at an average price of $67.41, for a total transaction of $133,134.75. Following the sale, the executive vice president now owns 28,832 shares in the company, valued at $1,943,565.12. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Brett A. Pletcher sold 1,486 shares of the business’s stock in a transaction on Thursday, March 11th. The stock was sold at an average price of $63.36, for a total transaction of $94,152.96. Following the completion of the sale, the executive vice president now owns 29,166 shares in the company, valued at approximately $1,847,957.76. The disclosure for this sale can be found here. 0.13% of the stock is owned by insiders.

Several brokerages have weighed in on GILD. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Friday. TheStreet upgraded shares of Gilead Sciences from a “c” rating to a “b-” rating in a report on Tuesday, March 30th. Sanford C. Bernstein upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a research note on Thursday, April 1st. Guggenheim upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a research note on Monday, January 4th. Finally, SVB Leerink increased their price target on shares of Gilead Sciences from $72.00 to $74.00 and gave the stock an “outperform” rating in a research note on Friday. Ten investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $98.21.

Shares of GILD traded up $0.46 on Tuesday, reaching $66.26. The company’s stock had a trading volume of 213,503 shares, compared to its average volume of 8,324,578. The company has a debt-to-equity ratio of 1.65, a current ratio of 3.25 and a quick ratio of 3.15. Gilead Sciences, Inc. has a 12-month low of $56.56 and a 12-month high of $81.76. The stock has a market capitalization of $83.43 billion, a P/E ratio of 67.84, a PEG ratio of 0.67 and a beta of 0.51. The stock’s 50 day simple moving average is $65.14 and its two-hundred day simple moving average is $62.74.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.02. Gilead Sciences had a net margin of 5.48% and a return on equity of 37.77%. Analysts expect that Gilead Sciences, Inc. will post 7.06 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 29th. Shareholders of record on Tuesday, June 15th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 4.29%. The ex-dividend date is Monday, June 14th. Gilead Sciences’s dividend payout ratio is currently 46.25%.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Recommended Story: Overbought

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.